

In the claims:

a1 Sub C1 1. (amended) A pharmaceutical composition for sustained release, said composition comprising a water soluble salt of fluvastatin as active ingredient and being selected from the group [comprising] consisting of matrix formulations, diffusion-controlled membrane coated formulations[;] and combinations thereof.

2. (amended) A pharmaceutical composition according to claim 1 wherein the [said] water soluble salt of fluvastatin is the sodium salt.

a2 Sub C2 4. (amended) A pharmaceutical composition according to claim 3 wherein the matrix material is selected from the group [comprising] consisting of polyethylene oxide, hydroxypropyl methyl cellulose and paraffin.

a3 Sub C3 6. (amended) A pharmaceutical composition according to claim 5 wherein the matrix material is selected from the group [comprising xanthane] consisting of xanthan and polyvinyl chloride.

a4 8. (amended) A pharmaceutical composition according to claim 7 wherein the material for film formation is selected from the group [comprising] consisting of ethyl cellulose, hydroxypropyl methyl cellulose and [hydroxypropyl] hydroxypropyl cellulose.

Cancel claims 9-11.